Am­gen sharp­ens fo­cus on ge­net­ic se­quenc­ing with $66M in­vest­ment

Re­in­forc­ing its abil­i­ty to iden­ti­fy and val­i­date dis­ease tar­gets, Am­gen $AMGN on Thurs­day said it would fork out £50 mil­lion ($66 mil­lion) to buy shares in pri­vate­ly-held Ox­ford Nanopore Tech­nolo­gies, which has de­vel­oped the first portable DNA/RNA se­quencer and has so far raised near­ly half a bil­lion pounds in fund­ing.

The new in­vest­ment builds on Am­gen’s ac­qui­si­tion of de­CODE Ge­net­ics back in 2012 for $415 mil­lion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.